Abstract

Drug development is a complex, resource-intensive process that is dictated by scientific, clinical and regulatory considerations. Regulatory requirements and development strategies can vary significantly across therapeutic areas due to differing disease biology, patient populations, medical practice, clinical endpoints and the degree of unmet medical need. These variations directly influence multiple aspects of drug development, including manufacturing, preclinical studies, the design of clinical trials, approval requirements and the availability of expedited regulatory pathways.

This article evaluates how drug development and regulatory pathways differ across major therapeutic areas, including oncology, rare diseases, paediatric indications and life-threatening conditions, within the jurisdictions of the US, the UK and the EU. Drawing on regulatory guidance and industry practices, it explores how the therapeutic context shapes strategies for drug development, trial design and regulatory approval. Key differences in regulatory expectations are highlighted, while also detailing incentives and mechanisms designed to accelerate development and approval. A nuanced understanding of these distinctions is critical for developing effective regulatory strategies and supporting stakeholders in navigating regulatory pathways and delivering therapies to patients, ultimately improving their quality of life.